Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation

YUKAKO ITO, ERIKO INOUE, YUKI MATSUI, SHINJI KOBUCHI, CHIAMI MOYAMA, KIKUKO AMAGASE, MAYUMI YOSHIMURA, YUZURU IKEHARA, SUSUMU NAKATA and HAYAO NAKANISHI
Anticancer Research December 2020, 40 (12) 6781-6789; DOI: https://doi.org/10.21873/anticanres.14701
YUKAKO ITO
1Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yukako{at}mb.kyoto-phu.ac.jp
ERIKO INOUE
1Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKI MATSUI
1Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJI KOBUCHI
1Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIAMI MOYAMA
2Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIKUKO AMAGASE
3Department of Pharmacy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAYUMI YOSHIMURA
4Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya University, Aichi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUZURU IKEHARA
5Department of Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSUMU NAKATA
2Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HAYAO NAKANISHI
4Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya University, Aichi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Characteristics of two types of orthotopic transplantation CTC mouse models to the pancreas. A. The first type is the surgical transplantation model. SUIT-2 cells in HBSS were directly injected into the pancreas pulled out through surgical incision of the abdominal wall. Primary tumours are located along the pancreas-omentum-spleen hilum. B. The second type is the intraperitoneal (ip) injection model. SUIT2-GFP cells in HBSS were ip injected into the near-pancreatic region by a 27G needle. Primary tumour was similarly located at the pancreasomental-spleen hilum. Subsequent progression such as peritoneal metastasis with ascites formation and liver/lung metastasis are clearly observed using GFP fluorescence. C. Histological examination shows primary tumours located at the pancreas-omental region and liver/lung metastasis. Inset: atypical glandular formation. Arrows indicate the primary and metastatic tumour. Bars indicate 20 μm. D: Comparison of the primary tumour and metastasis pattern between the two types of orthotopic CTC models. +; always present. +/–; sometimes present.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Characteristics of the heterotopic transplantation CTC mouse model. SUIT2-GFP cells in HBSS were injected subcutaneously. A. primary subcutaneous tumour on the back and lung metastases visualized using GFP fluorescence. The figure shows significantly higher number of lung metastases in heterotopic (sc) model than in orthotopic (pancreas) transplantation model. B. Histological examination confirms that the primary sc tumour and lung metastases are adenocarcinoma with glandular formation (arrows). Bars indicate 20 μm.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Detection of CTCs in the blood from the orthotopic and heterotopic mouse CTC models using a cytology-based CTC detection platform. A. Overview of the CTC detection procedure including filtration of CTCs using a 3D metal filter, transfer of CTCs to a glass slide, subsequent staining of CTCs, and the detection of CTCs using light microscopy. B. CTCs detected using cytokeratin (CK) or GFP immunocytochemistry and Papanicolaou (Pap) staining. Bars=20 μm. C: Representative CTCs from the orthotopic and heterotopic mouse models stained for CK and Pap. Arrows indicate a CTC cluster. Inset: single CTC. Bars=20 μm. D: Comparison of the CTC number between the two types of models. The CTC number in the heterotopic (sc) model tends to be higher than that of the orthotopic (pancreas) model, but not statistically significant (NS).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Analysis of the KRAS mutation in SUIT-2 cells and CTCs from the blood of the heterotopic (sc) xenograft mouse model. A. The procedure of CTC analysis includes pinpoint picking of the CTCs from a glass slide stained by Pap, extraction of DNA, and PCR analysis. B. Analysis of KRAS mutation in SUIT-2 cells using the cycleave PCR and direct sequencing. The result showed that SUIT-2 carry the KRAS G12D mutation at codon 12. C. Analysis of the KRAS G12D mutation of CTCs from the heterotopic mouse xenograft model by droplet-based digital PCR method. The blue and green dots (arrows) indicate droplets containing the amplified KRAS G12D mutant and wild-type alleles, respectively. The grey dots correspond to droplets without any mutant and wild-type alleles.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation
YUKAKO ITO, ERIKO INOUE, YUKI MATSUI, SHINJI KOBUCHI, CHIAMI MOYAMA, KIKUKO AMAGASE, MAYUMI YOSHIMURA, YUZURU IKEHARA, SUSUMU NAKATA, HAYAO NAKANISHI
Anticancer Research Dec 2020, 40 (12) 6781-6789; DOI: 10.21873/anticanres.14701

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation
YUKAKO ITO, ERIKO INOUE, YUKI MATSUI, SHINJI KOBUCHI, CHIAMI MOYAMA, KIKUKO AMAGASE, MAYUMI YOSHIMURA, YUZURU IKEHARA, SUSUMU NAKATA, HAYAO NAKANISHI
Anticancer Research Dec 2020, 40 (12) 6781-6789; DOI: 10.21873/anticanres.14701
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Prediction System for KRAS Mutation Detection in Circulating Tumor DNA in Unresectable Pancreatic Cancer
  • Google Scholar

More in this TOC Section

  • Ginsenoside Rh4 Induces Apoptosis Through ROS-Mediated Fas Signaling in Human Nasopharyngeal Carcinoma NPC/HK1 Cells
  • Genome-wide Analysis Highlights rs4671908 and rs2238431 as Predictors of Survival in Nasopharyngeal Carcinoma
  • Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma
Show more Experimental Studies

Keywords

  • CTC
  • Pancreatic cancer
  • KRAS mutation
  • mouse model
  • cytology
  • CTC detection platform
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire